About Insulet (NASDAQ:PODD)
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
Industry, Sector and Symbol
Industry Medical Prosthetics
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio-150.36
Forward P/E Ratio-174.84
Sales & Book Value
Annual Sales$366.99 million
Price / Sales11.92
Price / CashN/A
Book Value$1.10 per share
Price / Book68.35
Return on Equity-43.85%
Return on Assets-6.26%
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) issued its earnings results on Thursday, November, 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.06. The medical instruments supplier had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company's quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) earnings per share. View Insulet's Earnings History.
When will Insulet make its next earnings announcement?
Where is Insulet's stock going? Where will Insulet's stock price be in 2018?
16 analysts have issued 1 year price objectives for Insulet's shares. Their forecasts range from $44.00 to $80.00. On average, they expect Insulet's stock price to reach $62.14 in the next year. View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (1/9/2018)
- 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
- 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
- 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include Steris (STE), Juno Therapeutics (JUNO), William Demant Hol (WILYY), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), Neurocrine Biosciences (NBIX), SAGE Therapeutics (SAGE), Bioverativ (BIVV), Stada Arzneimittel (STDAF), Dr.Reddy's Laboratories (RDY), Grifols SA, Barcelona (GRFS), Icon (ICLR), United Therapeutics (UTHR), PRA Health Sciences (PRAH), Hill-Rom (HRC), Orion (ORINY), Catalent (CTLT) and BIO-TECHNE (TECH).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer (Age 65)
- Shacey Petrovic, President, Chief Operating Officer (Age 43)
- Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer (Age 43)
- Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development (Age 59)
- David Colleran J.D., Senior Vice President, General Counsel, Secretary (Age 45)
- Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering (Age 58)
- Charles Alpuche, Senior Vice President - Global Manufacturing and Operations (Age 57)
- Michael Spears, Senior Vice President - Quality and Regulatory Affairs (Age 52)
- Bret Christensen, Chief Commercial Officer
- Jessica Hopfield Ph.D., Lead Independent Director (Age 52)
Who owns Insulet stock?
Insulet's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (3.60%), Schwab Charles Investment Management Inc. (0.48%), KAMES CAPITAL plc (0.41%) and Diversified Trust Co (0.01%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, James C Mullen, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet.
Who bought Insulet stock? Who is buying Insulet stock?
Insulet's stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, KAMES CAPITAL plc, Schwab Charles Investment Management Inc. and Diversified Trust Co. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.
How do I buy Insulet stock?
Shares of Insulet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of Insulet stock can currently be purchased for approximately $75.18.
How big of a company is Insulet?
Insulet has a market capitalization of $4.37 billion and generates $366.99 million in revenue each year. The medical instruments supplier earns $-28,870,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Insulet employs 640 workers across the globe.
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (PODD)MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Insulet (NASDAQ:PODD) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.69||2.67||2.60||2.57|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$62.14||$60.77||$55.46||$47.42|
|Price Target Upside: ||9.62% downside||13.31% downside||8.97% downside||7.80% downside|
Insulet (NASDAQ:PODD) Consensus Price Target History
Insulet (NASDAQ:PODD) Analyst Ratings History
(Data available from 1/21/2016 forward)
Insulet (NASDAQ:PODD) Earnings History and Estimates Chart
Insulet (NASDAQ PODD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||($0.10)||($0.04)||$114.02 million||$121.80 million||View||N/A|
|8/3/2017||Q2 2017||($0.13)||($0.13)||$106.23 million||$110.00 million||View||Listen|
|5/8/2017||Q1 2017||($0.16)||($0.17)||$97.73 million||$101.70 million||View||Listen|
|2/27/2017||Q416||($0.05)||($0.16)||$100.61 million||$103.58 million||View||Listen|
|11/3/2016||Q316||($0.09)||($0.05)||$89.75 million||$94.90 million||View||N/A|
|8/3/2016||Q216||($0.17)||($0.08)||$81.10 million||$87.30 million||View||N/A|
|4/28/2016||Q116||($0.19)||($0.19)||$79.06 million||$81.21 million||View||Listen|
|2/25/2016||Q415||($0.26)||($0.48)||$91.89 million||$100.10 million||View||Listen|
|11/5/2015||Q315||($0.26)||($0.33)||$83.56 million||$87.30 million||View||Listen|
|8/12/2015||Q215||($0.13)||($0.27)||$70.32 million||$75.60 million||View||Listen|
|4/30/2015||Q115||($0.10)||($0.21)||$68.20 million||$61.20 million||View||N/A|
|2/26/2015||Q414||($0.04)||($0.10)||$73.52 million||$72.60 million||View||N/A|
|8/7/2014||Q214||($0.08)||($0.06)||$72.94 million||$72.00 million||View||N/A|
|5/7/2014||Q114||($0.06)||($0.11)||$68.47 million||$69.20 million||View||N/A|
|2/27/2014||Q413||($0.09)||($0.04)||$67.94 million||$68.53 million||View||N/A|
|11/7/2013||Q313||($0.16)||($0.39)||$62.01 million||$61.10 million||View||N/A|
|8/7/2013||Q2 2013||($0.19)||($0.20)||$60.47 million||$60.09 million||View||N/A|
|5/6/2013||Q1 2013||($0.21)||($0.20)||$57.26 million||$57.40 million||View||N/A|
|2/27/2013||Q4 2012||($0.21)||($0.21)||$59.12 million||$57.80 million||View||N/A|
|11/8/2012||Q312||($0.22)||($0.26)||$54.93 million||$54.80 million||View||N/A|
Insulet (NASDAQ:PODD) Earnings Estimates
2018 EPS Consensus Estimate: ($0.07)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Insulet (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.90%
Insulet (NASDAQ PODD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/13/2017||James C. Mullen||Director||Buy||2,500||$67.45||$168,625.00|| |
|9/6/2017||Charles Alpuche||EVP||Buy||2,500||$58.08||$145,200.00|| |
|5/16/2017||Michael P. Spears||SVP||Buy||2,500||$40.59||$101,475.00|| |
|5/11/2017||Bradley A. Thomas||EVP||Buy||3,000||$38.69||$116,070.00|| |
|5/11/2017||Jessica Hopfield||Director||Buy||2,580||$38.68||$99,794.40|| |
|5/1/2017||David A. Lemoine||Director||Sell||1,524||$43.40||$66,141.60|| |
|3/13/2017||Regina O. Sommer||Director||Sell||40,000||$45.00||$1,800,000.00|| |
|3/6/2017||David A. Lemoine||Director||Sell||1,282||$45.15||$57,882.30|| |
|3/2/2017||Joseph S. Zakrzewski||Director||Sell||40,000||$46.86||$1,874,400.00|| |
|12/9/2016||Charles Alpuche||SVP||Buy||6,600||$37.70||$248,820.00|| |
|12/2/2016||Patrick J. Sullivan||CEO||Buy||40,000||$33.89||$1,355,600.00|| |
|12/1/2016||Bradley A. Thomas||EVP||Buy||3,100||$32.45||$100,595.00|| |
|5/25/2016||Regina O Sommer||Director||Sell||8,019||$30.42||$243,937.98||20,330|| |
|5/18/2016||Patrick J Sullivan||CEO||Buy||45,000||$27.00||$1,215,000.00||202,795|| |
|5/13/2016||Bradley A Thomas||EVP||Buy||2,975||$26.63||$79,224.25||51,315|| |
|5/5/2016||Bradley A Thomas||EVP||Buy||1,656||$30.13||$49,895.28||48,340|| |
|3/10/2016||Daniel J Levangie||Insider||Sell||12,299||$30.89||$379,916.11||25,358|| |
|3/7/2016||Daniel J Levangie||Insider||Sell||7,663||$31.15||$238,702.45||9,813|| |
|3/2/2016||Jessica Hopfield||Director||Buy||3,230||$30.91||$99,839.30||8,838|| |
|6/5/2015||Patrick J Sullivan||CEO||Buy||10,000||$29.39||$293,900.00|| |
|5/28/2015||Patrick J Sullivan||CEO||Buy||20,000||$27.91||$558,200.00|| |
|5/15/2015||Timothy J Scannell||Director||Buy||3,500||$27.05||$94,675.00|| |
|5/5/2015||Bradley A Thomas||EVP||Buy||1,000||$27.26||$27,260.00|| |
|5/5/2015||Patrick Ryan||COO||Buy||3,669||$26.99||$99,026.31|| |
|4/2/2015||R Anthony Diehl||General Counsel||Sell||3,372||$30.96||$104,397.12|| |
|3/9/2015||Patrick J Sullivan||CEO||Buy||10,000||$31.93||$319,300.00|| |
|3/2/2015||Charles T Liamos||Director||Sell||4,000||$32.00||$128,000.00|| |
|2/12/2015||Charles T Liamos||Director||Sell||4,000||$32.00||$128,000.00|| |
|1/2/2015||Charles T Liamos||Director||Sell||4,000||$46.08||$184,320.00|| |
|11/3/2014||Charles T Liamos||Director||Sell||4,000||$42.95||$171,800.00|| |
|10/1/2014||Charles T Liamos||Director||Sell||4,000||$36.58||$146,320.00|| |
|10/1/2014||R Anthony Diehl||General Counsel||Sell||1,250||$36.59||$45,737.50|| |
|9/10/2014||Charles T Liamos||Director||Sell||4,000||$35.17||$140,680.00|| |
|9/2/2014||Duane Desisto||CEO||Sell||20,000||$36.30||$726,000.00|| |
|8/1/2014||Duane Desisto||CEO||Sell||20,000||$34.23||$684,600.00|| |
|7/1/2014||Duane Desisto||CEO||Sell||20,000||$40.52||$810,400.00|| |
|7/1/2014||R Anthony Diehl||General Counsel||Sell||1,250||$39.65||$49,562.50|| |
|6/11/2014||R Anthony Diehl||General Counsel||Sell||17,871||$37.09||$662,835.39|| |
|6/9/2014||Peter Devlin||Insider||Sell||12,314||$37.10||$456,849.40|| |
|4/8/2014||Peter Devlin||Insider||Sell||30,000||$41.25||$1,237,500.00||79,668|| |
|4/3/2014||R Anthony Diehl||General Counsel||Sell||4,617||$48.67||$224,709.39||53,246|| |
|3/6/2014||R Anthony Diehl||General Counsel||Sell||12,458||$49.28||$613,930.24||58,246|| |
|3/6/2014||Tracey Haas Wielinski||VP||Sell||8,275||$49.21||$407,212.75||24,000|| |
|2/3/2014||Charles Liamos||Director||Sell||11,037||$42.93||$473,818.41||77,316|| |
|2/3/2014||Duane Desisto||CEO||Sell||20,000||$42.95||$859,000.00||184,293|| |
|2/3/2014||Peter Devlin||Insider||Sell||30,000||$42.82||$1,284,600.00||63,081|| |
|1/3/2014||Charles Liamos||COO||Sell||86,000||$36.02||$3,097,720.00||77,316|| |
|1/2/2014||Duane Desisto||CEO||Sell||20,000||$36.07||$721,400.00||184,293|| |
|12/3/2013||Charles Liamos||COO||Sell||63,808||$36.26||$2,313,678.08||118,194|| |
|11/18/2013||Charles Liamos||COO||Sell||80,000||$35.60||$2,848,000.00||118,194|| |
|9/3/2013||Duane Desisto||CEO||Sell||20,000||$33.38||$667,600.00||182,433|| |
|8/29/2013||Sally Crawford||Director||Sell||9,000||$33.42||$300,780.00||7,000|| |
|8/15/2013||Regina Sommer||Director||Sell||5,000||$33.32||$166,600.00||16,500|| |
|8/1/2013||Duane Desisto||CEO||Sell||20,000||$31.85||$637,000.00|| |
|7/1/2013||Duane Desisto||CEO||Sell||20,000||$31.51||$630,200.00|| |
|7/1/2013||Peter Devlin||Insider||Sell||30,000||$31.48||$944,400.00|| |
|6/14/2013||Sally Crawford||Director||Sell||31,000||$30.47||$944,570.00|| |
|6/10/2013||R Anthony Diehl||General Counsel||Sell||38,455||$30.50||$1,172,877.50|| |
|6/3/2013||Duane Desisto||CEO||Sell||20,000||$29.76||$595,200.00|| |
|12/3/2012||Brian K Roberts||CFO||Sell||10,000||$21.92||$219,200.00|| |
|11/1/2012||Brian K Roberts||CFO||Sell||10,000||$21.49||$214,900.00|| |
|9/4/2012||Brian K Roberts||CFO||Sell||10,000||$20.78||$207,800.00|| |
|9/4/2012||Duane Desisto||CEO||Sell||20,000||$20.97||$419,400.00|| |
|9/4/2012||Ruthann Depietro||VP||Sell||1,000||$20.90||$20,900.00|| |
Insulet (NASDAQ PODD) News Headlines
Insulet (NASDAQ:PODD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement
Insulet (NASDAQ PODD) Stock Chart for Sunday, January, 21, 2018